Origami Therapeutics mission and therapeutic theory for neurodegenerative disease
Origami Therapeutics looks strikingly stable across these two snapshots. In August 2018, the company said the core move in neurodegenerative disease was to repair the mutant protein itself with small molecules that reshape and stabilize misfolded proteins. In January 2020, it said almost the same thing: treat diseases driven by mutant proteins by restoring the protein, using small molecules to reshape misfolded or altered proteins. What changed is mostly framing, not doctrine. The 2018 language leans on protein stabilization and on showing benefit through a protein-repair approach. The 2020 language shifts slightly toward restoring normal protein function and physiological balance. That reads like a modest refinement of how the mechanism and downstream effect are described, not a new therapeutic theory. The clinical strategy also stays steady. In both versions, the company focuses on genetic disease and says natural history should guide patient selection, treatment timing, and endpoints. We do not see a pivot in target class, modality, or disease logic here. Evidence is thin because there are only two website statements, and both appear to be polished top-level messaging rather than detailed scientific updates. Based on these records alone, the belief evolution is minimal: the mission stayed fixed, and the later version mainly tightens the wording around functional restoration.